Virginie Nägele

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

P. Kufer, A. Wolf, P. Baeuerle, 2017, Experimental Hematology & Oncology.

Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events.

H. Lassmann, P. Kufer, G. Zugmaier, 2019, Cancer research.

The relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab.

P. Kufer, G. Zugmaier, R. Bargou, 2021, Experimental hematology.

Neisseria meningitidis adhesin NadA targets beta1 integrins: functional similarity to Yersinia invasin.

J. Heesemann, O. Kurzai, S. Schielke, 2011, The Journal of biological chemistry.

Neisseria meningitidis Adhesin NadA Targets β1 Integrins

J. Heesemann, O. Kurzai, S. Schielke, 2011, Journal of Biological Chemistry.

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).

P. Bogner, P. Kufer, T. Raum, 2019, Journal of Clinical Oncology.

Expression of the meningococcal adhesin NadA is controlled by a transcriptional regulator of the MarR family

O. Kurzai, M. Frosch, S. Schielke, 2009, Molecular microbiology.

Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

A. Schub, P. Kufer, A. Wolf, 2013 .